LLY

775.43

-0.58%↓

UNH

503.39

+4.2%↑

NVO

107.93

-0.75%↓

JNJ

146.06

+0.54%↑

ABBV

175.52

+0.97%↑

LLY

775.43

-0.58%↓

UNH

503.39

+4.2%↑

NVO

107.93

-0.75%↓

JNJ

146.06

+0.54%↑

ABBV

175.52

+0.97%↑

LLY

775.43

-0.58%↓

UNH

503.39

+4.2%↑

NVO

107.93

-0.75%↓

JNJ

146.06

+0.54%↑

ABBV

175.52

+0.97%↑

LLY

775.43

-0.58%↓

UNH

503.39

+4.2%↑

NVO

107.93

-0.75%↓

JNJ

146.06

+0.54%↑

ABBV

175.52

+0.97%↑

LLY

775.43

-0.58%↓

UNH

503.39

+4.2%↑

NVO

107.93

-0.75%↓

JNJ

146.06

+0.54%↑

ABBV

175.52

+0.97%↑

Search

Merck & Co Inc.

Abierto

Sector Salud

100.16 -0.36

Resumen

Variación precio

24h

Actual

Mínimo

99.59

Máximo

101.41

Métricas clave

By Trading Economics

Ingresos

-2.3B

3.2B

Ventas

550M

17B

P/B

Media del Sector

137.56

87.008

BPA

1.57

Rentabilidad por dividendo

2.712

Margen de beneficio

18.95

Empleados

72,000

EBITDA

-1.4B

6.1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+29.56 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.71%

2.48%

Próximas Ganancias

4 feb 2025

Fecha Próximo Dividendo

8 ene 2025

Próxima Fecha de Ex Dividendo

13 mar 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

431M

258B

Apertura anterior

100.52

Cierre anterior

100.16

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

178 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Merck & Co Inc. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2024, 14:04 UTC

Adquisiciones, fusiones, absorciones

Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences

19 nov 2024, 12:08 UTC

Principales Noticias

Merck Says Blockbuster Cancer Drug Met Main Goals In Trial Of New Under-The-Skin Formulation -- MarketWatch

31 oct 2024, 12:07 UTC

Principales Noticias
Ganancias

Update: Merck Tops Earnings Estimates but Lowers Full-Year Guidance -- Barrons.com

31 oct 2024, 10:49 UTC

Principales Noticias
Ganancias

Merck Tops Earnings Estimates but Lowers Full-Year Guidance -- Barrons.com

31 oct 2024, 10:31 UTC

Ganancias

Merck Posts 79c/Share 3Q Charge Related to Business Development Transactions >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Januvia/Janumet Sales Down 42% >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Animal Health Sales $1.49B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Keytruda Sales $7.43B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Pharmaceutical Sales $14.94B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Pharmaceutical Sales Up 5% >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Net $3.16B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Gardasil/Gardasil 9 Sales $2.31B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Adj EPS $1.57 >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q EPS $1.24 >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Gardasil/Gardasil 9 Sales Down 11% >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Januvia/Janumet Sales $482M >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck Sees FY Rev $63.6B-$64.1B >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Keytruda Sales Up 17% >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck Sees FY Adj EPS $7.72-Adj EPS $7.77 >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Animal Health Sales Up 6% >MRK

31 oct 2024, 10:30 UTC

Ganancias

Merck 3Q Sales $16.7B >MRK

24 oct 2024, 13:50 UTC

Adquisiciones, fusiones, absorciones

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

3 oct 2024, 19:02 UTC

Adquisiciones, fusiones, absorciones

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

3 oct 2024, 18:20 UTC

Adquisiciones, fusiones, absorciones

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

1 oct 2024, 10:46 UTC

Adquisiciones, fusiones, absorciones

Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK

1 oct 2024, 10:46 UTC

Adquisiciones, fusiones, absorciones

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical

30 sept 2024, 21:02 UTC

Principales Noticias

FOMO on China Stock Rally? Think Twice About Buying In. -- Barrons.com

12 sept 2024, 15:02 UTC

Principales Noticias

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12 sept 2024, 10:00 UTC

Principales Noticias

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

9 sept 2024, 17:55 UTC

Principales Noticias

A Better Drug Than Merck's Blockbuster Keytruda? Not So Fast -- WSJ

Comparación entre iguales

Cambio de precio

Merck & Co Inc. Esperado

Precio Objetivo

By TipRanks

29.56% repunte

Estimación a 12 meses

Media 129.64 USD  29.56%

Máximo 150 USD

Mínimo 110 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

13

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

100.05 / 102.45Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

178 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.